Nothing Special   »   [go: up one dir, main page]

MX2012004133A - Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas. - Google Patents

Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.

Info

Publication number
MX2012004133A
MX2012004133A MX2012004133A MX2012004133A MX2012004133A MX 2012004133 A MX2012004133 A MX 2012004133A MX 2012004133 A MX2012004133 A MX 2012004133A MX 2012004133 A MX2012004133 A MX 2012004133A MX 2012004133 A MX2012004133 A MX 2012004133A
Authority
MX
Mexico
Prior art keywords
compositions
methods
adjuvant
macrolide
proteinaceous antigen
Prior art date
Application number
MX2012004133A
Other languages
English (en)
Inventor
Nahla Fattohi
Terry Kaleung Ng
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2012004133A publication Critical patent/MX2012004133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones que comprenden un adyuvante de aceite, una lactona macrocíclica eficaz para la prevención o combate de una infección parasitaria en un animal de sangre caliente y una cantidad inmunizante de al menos un polipéptido inmunogénico y a procedimientos de uso de las mismas.
MX2012004133A 2009-10-07 2010-09-29 Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas. MX2012004133A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24945409P 2009-10-07 2009-10-07
PCT/US2010/050630 WO2011043962A2 (en) 2009-10-07 2010-09-29 Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012004133A true MX2012004133A (es) 2012-05-08

Family

ID=43707921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004133A MX2012004133A (es) 2009-10-07 2010-09-29 Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.

Country Status (9)

Country Link
US (1) US20110091559A1 (es)
EP (1) EP2485725A2 (es)
AR (1) AR078539A1 (es)
AU (1) AU2010303741A1 (es)
BR (1) BR112012008185A2 (es)
MX (1) MX2012004133A (es)
TW (1) TW201127398A (es)
UY (1) UY32930A (es)
WO (1) WO2011043962A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3028048B1 (en) * 2013-07-31 2018-09-26 BioVentures, LLC Compositions for treating and preventing cancer targeting tumor associated carbohydrate antigens
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
GB201714057D0 (en) * 2017-09-01 2017-10-18 Univ College Dublin Nat Univ Of Ireland Dublin A fasciola hepatica antigen and vaccine
CN110898216B (zh) * 2019-12-31 2021-12-03 中国农业科学院兰州兽医研究所 重组旋毛虫硫氧还蛋白过氧化物酶2在制备抗旋毛虫感染疫苗中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US4853372A (en) 1983-12-22 1989-08-01 Merck & Co., Inc. Non-aqueous ivermectin formulation with improved antiparasitic activity
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US4886828A (en) 1986-09-12 1989-12-12 American Cyanamid Company Δ22 -derivatives of LL-F28249 compounds
US5019589A (en) 1986-09-12 1991-05-28 American Cyanamid Company Δ23 -LL-F28249 compounds
GB8813150D0 (en) 1988-06-03 1988-07-06 American Cyanamid Co Chemical compounds
ES2052173T3 (es) * 1989-04-11 1994-07-01 Pfizer Composiciones inyectables que contienen 25-cyclohexil-avermectina b1.
NZ234802A (en) 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5055486A (en) 1989-12-22 1991-10-08 American Cyanamid Company 13-alkyl-23-imino derivative of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents
US5030650A (en) 1989-09-11 1991-07-09 American Cyanamid Company 13-halo-23-imino derivatives of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents
EP0525307B1 (en) 1991-07-23 1996-03-06 American Cyanamid Company Stable compositions for parenteral administration and their use
NZ257148A (en) * 1992-10-21 1996-04-26 Mallinckrodt Veterinary Inc Anthelmintic vaccine containing a cathepsin l type protease
JPH07505787A (ja) * 1993-02-05 1995-06-29 ダラテク・プロプライエタリー・リミテッド ファスキオラ種から取得可能なポリペプチド類，およびワクチン，処置法およびそのｄｎａ配列
GB9312324D0 (en) 1993-06-15 1993-07-28 Pitman Moore Inc Vaccine
AU7349596A (en) 1995-05-17 1996-12-11 International Centre of Insect Physiology and Ecology, The Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
DE69619894T2 (de) * 1995-06-30 2002-11-14 American Cyanamid Co., Madison Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
DE69636706T2 (de) * 1995-09-25 2007-10-11 Ashmont Holdings Ltd., Takapuna Makrocyclische lacton anthelmintika
ATE252316T1 (de) * 1996-06-05 2003-11-15 Ashmont Holdings Ltd Injizierbare zusammensetzungen
GB9612214D0 (en) 1996-06-11 1996-08-14 Mallinckrodt Veterinary Inc Vaccine
WO2003061555A2 (en) * 2001-07-27 2003-07-31 Wyeth West nile vaccine
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition

Also Published As

Publication number Publication date
EP2485725A2 (en) 2012-08-15
TW201127398A (en) 2011-08-16
AR078539A1 (es) 2011-11-16
BR112012008185A2 (pt) 2016-08-16
AU2010303741A1 (en) 2012-04-19
US20110091559A1 (en) 2011-04-21
WO2011043962A2 (en) 2011-04-14
WO2011043962A3 (en) 2011-06-03
UY32930A (es) 2011-05-31

Similar Documents

Publication Publication Date Title
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
EA201001479A1 (ru) Вакцина
EP2545068B8 (en) Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease
WO2006133879A3 (en) Vaccines for immunization against helicobacter
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
PH12014501835A1 (en) Novel adjuvant compositions
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
MX2019003004A (es) Composiciones para inmunizacion contra staphylococcus aureus.
NZ700477A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2006091722A3 (en) Alkyl-glycoside enhanced vaccination
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
WO2012067866A8 (en) Multivalent vaccine for filariasis
MX2012004133A (es) Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
WO2011007359A3 (en) Antigen specific multi epitope -based anti-infective vaccines
EA201001478A1 (ru) Вакцина
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
WO2009037262A3 (en) Method of preventing early lawsonia intracellularis infections
WO2008044149A3 (en) Shigella ipad protein and its use as a vaccine against shigella infection
WO2007120860A3 (en) Nanoemulsion vaccines
WO2012075104A3 (en) Novel non-primate hepacivirus
WO2011011725A3 (en) Use of toxoplasma and derived compositions to prevent or treat microbial infections
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
EP2433648A3 (en) Vaccine comprising an oil in water emulsion adjuvant

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ZOETIS W LLC

HC Change of company name or juridical status

Owner name: ZOETIS W LLC

FA Abandonment or withdrawal